United Therapeutics (UTHR) Reports Q3: Everything You Need To Know Ahead Of Earnings

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings this Wednesday before the bell. Here’s what to look for.

United Therapeutics missed analysts’ revenue expectations by 0.5% last quarter, reporting revenues of $798.6 million, up 11.7% year on year. It was a softer quarter for the company, with a significant miss of analysts’ EPS estimates and a slight miss of analysts’ revenue estimates.

Is United Therapeutics a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting United Therapeutics’s revenue to grow 8.4% year on year to $812.2 million, slowing from the 22.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $7.31 per share.United Therapeutics Total Revenue

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. United Therapeutics has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 3.8% on average.

Looking at United Therapeutics’s peers in the biotechnology segment, only BioMarin Pharmaceutical has reported results so far. It met analysts’ revenue estimates, delivering year-on-year sales growth of 4.1%.

Read our full analysis of BioMarin Pharmaceutical’s earnings results here.

There has been positive sentiment among investors in the biotechnology segment, with share prices up 7% on average over the last month. United Therapeutics’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $492.85 (compared to the current share price of $421).

Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Ver comentarios